Peking University
Clinical trials sponsored by Peking University, explained in plain language.
-
New combo therapy aims to boost success of bile duct cancer surgery
Disease control TerminatedThis study tested a treatment given before surgery for bile duct cancer that has a high risk of coming back. The goal was to see if a combination of targeted liver chemotherapy, an immunotherapy drug (atezolizumab), and a blood vessel blocker (bevacizumab) could shrink tumors and…
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New combo therapy trial for tough liver cancers halted early
Disease control TerminatedThis study aimed to see if adding a specific type of chemotherapy directly into the liver's blood vessels (HAIC) before a standard artery-blocking treatment (TACE) and a targeted drug (donafenib) works better than just TACE plus the drug. It was for people with a specific advance…
Phase: PHASE2, PHASE3 • Sponsor: Peking University • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
First human test of CAR-T therapy targets tough digestive cancers
Disease control TerminatedThis early-stage study tested a new type of personalized immune cell therapy called LCAR-G08 in 17 adults with advanced cancers of the digestive system (like colorectal or stomach cancer). The main goals were to find the safest dose and see how well the body handled the treatment…
Phase: PHASE1 • Sponsor: Peking University • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC